- Home
- BMEA vs AP Comparison
BMEA vs AP Comparison
Compare BMEA & AP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BMEA
- AP
- Stock Information
- Founded
- BMEA 2017
- AP 1929
- Country
- BMEA United States
- AP United States
- Employees
- BMEA N/A
- AP N/A
- Industry
- BMEA Biotechnology: Pharmaceutical Preparations
- AP Fluid Controls
- Sector
- BMEA Health Care
- AP Industrials
- Exchange
- BMEA Nasdaq
- AP Nasdaq
- Market Cap
- BMEA 65.8M
- AP 54.7M
- IPO Year
- BMEA 2021
- AP N/A
- Fundamental
- Price
- BMEA $1.44
- AP $3.01
- Analyst Decision
- BMEA Strong Buy
- AP
- Analyst Count
- BMEA 11
- AP 0
- Target Price
- BMEA $27.60
- AP N/A
- AVG Volume (30 Days)
- BMEA 703.1K
- AP 68.7K
- Earning Date
- BMEA 05-05-2025
- AP 05-12-2025
- Dividend Yield
- BMEA N/A
- AP N/A
- EPS Growth
- BMEA N/A
- AP N/A
- EPS
- BMEA N/A
- AP 0.22
- Revenue
- BMEA N/A
- AP $412,355,000.00
- Revenue This Year
- BMEA N/A
- AP N/A
- Revenue Next Year
- BMEA N/A
- AP N/A
- P/E Ratio
- BMEA N/A
- AP $13.97
- Revenue Growth
- BMEA N/A
- AP N/A
- 52 Week Low
- BMEA $1.29
- AP $0.74
- 52 Week High
- BMEA $13.07
- AP $3.43
- Technical
- Relative Strength Index (RSI)
- BMEA 39.69
- AP 62.08
- Support Level
- BMEA $1.29
- AP $2.85
- Resistance Level
- BMEA $1.52
- AP $3.13
- Average True Range (ATR)
- BMEA 0.14
- AP 0.30
- MACD
- BMEA 0.01
- AP 0.02
- Stochastic Oscillator
- BMEA 28.17
- AP 66.13
About BMEA Biomea Fusion Inc.
Biomea Fusion Inc is a clinical-stage diabetes and obesity medicines company focused on the discovery and development of oral covalent small-molecule drugs to treat patients with metabolic diseases. The company uses its proprietary FUSION System discovery platform to develop a pipeline of novel small-molecule product candidates. Its principal clinical program's drug candidate, icovamenib, is being developed as an orally bioavailable, selective covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity. The company is also developing BMF-650, an investigational, oral small-molecule GLP-1 RA, which has the potential to be a therapeutic option for diabetes and obesity.
About AP Ampco-Pittsburgh Corporation
Ampco-Pittsburgh Corp is manufacturing and selling engineered, specialty metal products and customized equipment. It operates in two business segments namely the Forged and Cast Engineered Products segment and the Air and Liquid Processing segment. The Forged and Cast Engineered Products segment produces forged hardened steel rolls, cast rolls, and open-die forged products. Forged hardened steel rolls are used in cold rolling mills by producers of steel, aluminum, and other metals whereas, the Air and Liquid Processing segment includes Aerofin, Buffalo Air Handling, and Buffalo Pumps. The company generates a majority of its revenue from the Forged and Cast Engineered Products segment. It has a business presence in the United States and other countries.